Cepheid Loses Influenza Dx Contract with CDC | GenomeWeb
This article and headline have been updated from a previous version, which incorrectly stated that the terminated contract was worth $2.4 million. That was the value for the first two phases of the project, which were completed successfully, a company spokesperson said.
 
NEW YORK (GenomeWeb News) - Cepheid today said its contract with the Centers for Disease Control and Prevention to develop an influenza virus diagnostic has been terminated.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.